MY138883A - Use of asiatic acid for treatment of cencer - Google Patents
Use of asiatic acid for treatment of cencerInfo
- Publication number
- MY138883A MY138883A MYPI20003987A MYPI20003987A MY138883A MY 138883 A MY138883 A MY 138883A MY PI20003987 A MYPI20003987 A MY PI20003987A MY PI20003987 A MYPI20003987 A MY PI20003987A MY 138883 A MY138883 A MY 138883A
- Authority
- MY
- Malaysia
- Prior art keywords
- treatment
- cencer
- asiatic acid
- asiatic
- acid
- Prior art date
Links
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 title abstract 2
- 229940011658 asiatic acid Drugs 0.000 title abstract 2
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 title abstract 2
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 title abstract 2
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 abstract 1
- 229940022757 asiaticoside Drugs 0.000 abstract 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI20003987A MY138883A (en) | 2000-08-29 | 2000-08-29 | Use of asiatic acid for treatment of cencer |
| AU2001247968A AU2001247968A1 (en) | 2000-08-29 | 2001-02-14 | Use of asiatic acid or asiaticoside for treatment of cancer |
| US10/362,720 US20040097463A1 (en) | 2000-08-29 | 2001-02-14 | Use of asiatic acid or asiaticoside for treatment of cancer |
| PCT/US2001/040103 WO2002017904A1 (en) | 2000-08-29 | 2001-02-14 | Use of asiatic acid or asiaticoside for treatment of cancer |
| AT01920974T ATE415962T1 (de) | 2000-08-29 | 2001-02-14 | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs |
| DE60136826T DE60136826D1 (de) | 2000-08-29 | 2001-02-14 | Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs |
| DK01920974T DK1313462T3 (da) | 2000-08-29 | 2001-02-14 | Anvendelse af asiatisk syre eller asiaticosid til behandling af cancer |
| EP01920974A EP1313462B1 (en) | 2000-08-29 | 2001-02-14 | Use of asiatic acid or asiaticoside for treatment of cancer |
| JP2002522878A JP2004507496A (ja) | 2000-08-29 | 2001-02-14 | 癌治療のためのアジア酸またはアジアチコサイドの使用。 |
| JP2011256721A JP5421340B2 (ja) | 2000-08-29 | 2011-11-24 | 癌治療のためのアジア酸またはアジアチコサイドの使用。 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MYPI20003987A MY138883A (en) | 2000-08-29 | 2000-08-29 | Use of asiatic acid for treatment of cencer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY138883A true MY138883A (en) | 2009-08-28 |
Family
ID=19749475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20003987A MY138883A (en) | 2000-08-29 | 2000-08-29 | Use of asiatic acid for treatment of cencer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040097463A1 (enExample) |
| EP (1) | EP1313462B1 (enExample) |
| JP (2) | JP2004507496A (enExample) |
| AT (1) | ATE415962T1 (enExample) |
| AU (1) | AU2001247968A1 (enExample) |
| DE (1) | DE60136826D1 (enExample) |
| DK (1) | DK1313462T3 (enExample) |
| MY (1) | MY138883A (enExample) |
| WO (1) | WO2002017904A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030144312A1 (en) * | 2001-10-30 | 2003-07-31 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant cancer cells |
| KR100571886B1 (ko) | 2004-02-23 | 2006-04-17 | 학교법인 영남학원 | 아시아틱산을 포함하는 피부암 예방 또는 치료용 조성물 |
| JP2007523956A (ja) | 2004-02-25 | 2007-08-23 | ダナ−ファーバー キャンサー インスティテュート インク． | 腫瘍細胞増殖を阻害するための方法 |
| WO2006012015A2 (en) * | 2004-06-29 | 2006-02-02 | Oregon Health And Science University | Methods and compositions for nerve regeneration |
| US20070010459A1 (en) * | 2005-01-14 | 2007-01-11 | Ying Liu | Application of asiatic acid and its derivatives to treat pulmonary fibrosis |
| US20090018146A1 (en) * | 2005-01-27 | 2009-01-15 | Research Development Corporation | Combination Therapy with Triterpenoid Compounds and Proteasome Inhibitors |
| JP5539224B2 (ja) * | 2008-01-11 | 2014-07-02 | シャンハイ・インスティチュート・オブ・ファーマシューティカル・インダストリー（エスアイピーアイ） | アジアティック酸（ａｓｉａｔｉｃａｃｉｄ）及びその選択される塩に基づく治療用製剤 |
| US9146238B2 (en) | 2008-04-16 | 2015-09-29 | The Johns Hopkins University | Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants |
| US8835506B2 (en) | 2008-06-05 | 2014-09-16 | Stc.Unm | Methods and related compositions for the treatment of cancer |
| MX341872B (es) | 2009-12-21 | 2016-09-06 | Pirelli | Proceso y planta para construir llantas. |
| AU2010354973B2 (en) * | 2010-06-10 | 2015-01-22 | Indus Biotech Private Limited | A method for preparation of highly pure asiaticoside composition from Centella asiatica and a method of use thereof |
| TR201816243T4 (tr) * | 2011-01-31 | 2018-11-21 | Lucolas M D Ltd | Aromataz inhibitörlerinin ve antioksidanların kombinasyonları. |
| US20140194368A1 (en) * | 2013-01-04 | 2014-07-10 | Beech Tree Labs, Inc. | Method of Treating Cancer by Administration of Low Levels of Heat Shock Protein 70 (HSP70) |
| KR20150127720A (ko) | 2013-03-14 | 2015-11-17 | 유니버시티 오브 매릴랜드, 발티모어 | 안드로겐 수용체 하향 조절제 및 그의 용도 |
| US10357483B2 (en) | 2013-05-03 | 2019-07-23 | Selecta Biosciences, Inc. | Methods comprising dosing combinations for reducing undesired humoral immune responses |
| EP3033088A4 (en) | 2013-08-12 | 2017-03-08 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| WO2015179404A1 (en) | 2014-05-19 | 2015-11-26 | The Johns Hopkins University | Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer |
| EP3186393A4 (en) * | 2014-08-25 | 2018-01-10 | The Johns Hopkins University | Methods and compositions related to prostate cancer therapeutics |
| EP3124047A1 (en) * | 2015-07-28 | 2017-02-01 | Merz Pharma GmbH & Co. KGaA | Pentacyclic triterpenoids for injection lipolysis |
| US20180228815A1 (en) * | 2016-11-09 | 2018-08-16 | The Chinese University Of Hong Kong | Naringenin and asiatic acid combination treatment of cancers |
| CA3055936A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| WO2019200585A1 (en) * | 2018-04-19 | 2019-10-24 | The Chinese University Of Hong Kong | Naringenin and asiatic acid combination treatment of cancers |
| WO2020078453A1 (en) * | 2018-10-18 | 2020-04-23 | Sinomab Bioscience Limited | Methods of treating rheumatoid arthritis |
| CN109528735B (zh) * | 2019-01-30 | 2021-03-12 | 中国药科大学 | 积雪草苷在制备治疗皮肤癌药物中的新用途 |
| CN110200981A (zh) * | 2019-06-06 | 2019-09-06 | 中国药科大学 | 五环三萜皂苷的医药用途及其药物组合物 |
| US20240034788A1 (en) * | 2020-08-20 | 2024-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Abscopal therapy for cancer |
| WO2025188669A1 (en) * | 2024-03-04 | 2025-09-12 | Cardiff Oncology, Inc. | Use of plk1 inhibitor as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB923414A (en) * | 1960-04-13 | 1963-04-10 | Laroche Navarron Lab | Therapeutic compositions comprising asiatic and arjunolic acids |
| IT1203515B (it) * | 1987-02-26 | 1989-02-15 | Indena Spa | Complessi di saponine con fosfolipidi e composizioni farmaceutiche e cosmetiche che li contengono |
| EP0383171A3 (en) * | 1989-02-11 | 1991-07-24 | Hoechst Aktiengesellschaft | 2,3,23-trihydroxy-urs-12-ene derivatives for treating cognitive disorders |
| FR2714598B1 (fr) * | 1993-12-30 | 1996-02-09 | Oreal | Composition amincissante à deux types de liposomes pour traitement topique, son utilisation. |
| JPH08133952A (ja) * | 1994-11-07 | 1996-05-28 | Shiseido Co Ltd | 皮膚外用剤 |
| EP0944571B1 (en) * | 1996-11-27 | 2001-06-13 | Dong Kook Pharmaceutical Co., Ltd. | Asiatic acid derivatives having modified a-ring |
| IT1288257B1 (it) * | 1996-11-29 | 1998-09-11 | Paoli Ambrosi Gianfranco De | Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico |
| FR2763336B1 (fr) * | 1997-05-14 | 1999-08-06 | Lvmh Rech | Esters de tocopherol et leurs utilisations en cosmetique et pharmacie |
| AU2005251463A1 (en) * | 2004-06-14 | 2005-12-22 | Zoser B. Salama | Anti-cancer composition comprising proline or its derivatives and an anti-tumour antibody |
-
2000
- 2000-08-29 MY MYPI20003987A patent/MY138883A/en unknown
-
2001
- 2001-02-14 AT AT01920974T patent/ATE415962T1/de not_active IP Right Cessation
- 2001-02-14 AU AU2001247968A patent/AU2001247968A1/en not_active Abandoned
- 2001-02-14 DK DK01920974T patent/DK1313462T3/da active
- 2001-02-14 WO PCT/US2001/040103 patent/WO2002017904A1/en not_active Ceased
- 2001-02-14 JP JP2002522878A patent/JP2004507496A/ja active Pending
- 2001-02-14 EP EP01920974A patent/EP1313462B1/en not_active Expired - Lifetime
- 2001-02-14 DE DE60136826T patent/DE60136826D1/de not_active Expired - Lifetime
- 2001-02-14 US US10/362,720 patent/US20040097463A1/en not_active Abandoned
-
2011
- 2011-11-24 JP JP2011256721A patent/JP5421340B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004507496A (ja) | 2004-03-11 |
| EP1313462A1 (en) | 2003-05-28 |
| DK1313462T3 (da) | 2009-03-30 |
| AU2001247968A1 (en) | 2002-03-13 |
| DE60136826D1 (de) | 2009-01-15 |
| WO2002017904A1 (en) | 2002-03-07 |
| US20040097463A1 (en) | 2004-05-20 |
| JP2012092110A (ja) | 2012-05-17 |
| EP1313462B1 (en) | 2008-12-03 |
| ATE415962T1 (de) | 2008-12-15 |
| JP5421340B2 (ja) | 2014-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY138883A (en) | Use of asiatic acid for treatment of cencer | |
| IL144294A0 (en) | P53 inhibitors and therapeutic use of the same | |
| MY155218A (en) | Small molecules useful in the treatment of inflammatory disease | |
| AU2072201A (en) | Agents and methods for the treatment of proliferative diseases | |
| AU2002236765A1 (en) | Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent | |
| AU6998791A (en) | Use of n-myristoyl-(s)-phenylalanine for obtaining medicinal products intended for the treatment of diseases involving myristoylation | |
| MY135766A (en) | Quinolinones and naphthyridinones for treating inflammatory diseases | |
| SG144712A1 (en) | Nordihydroguaiartic derivaties for use in treatment of tumors | |
| MY164077A (en) | Compositions and uses of et743 for treating cancer | |
| AU2002239491A1 (en) | Methods for the treatment of cancer and other diseases and methods of developing the same | |
| GB9521608D0 (en) | Pharmaceutical composition | |
| GB0020504D0 (en) | Therapeutic method | |
| GB9923078D0 (en) | Sapogenin derivatives and their use | |
| GB9907571D0 (en) | Compounds | |
| AU3919001A (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers | |
| AU2002352566A1 (en) | Use of corrinoids in the treatment of skin diseases | |
| DE60006284D1 (de) | Arzneimittel zur behandlung konvulsivischer zustände | |
| GB9723824D0 (en) | Cytostatic agents | |
| AU2450900A (en) | Therapeutic nucleoside compound | |
| AU2002241416A1 (en) | Dermatological agent for the treatment of skin trauma, especially in burn conditions | |
| UA32241A (uk) | Спосіб лікування запалювальних процесів у експериментальних тварин | |
| MXPA02000485A (es) | 2-amino-benzoxazinonas para el tratamiento del virus de herpes simple. | |
| AU2003209489A1 (en) | Medical use of captopril for the treatment and prophylaxis of cancer | |
| UA32315A (uk) | Спосіб накладання шкірного шва | |
| AUPR171000A0 (en) | Composition for the treatment of infectious and/or skin diseases |